A study published in the New England Journal of Medicine found that omitting biopsy in patients with negative MRI results reduces the risk of detecting clinically insignificant prostate cancer. The study involved men aged 50 to 60 who underwent PSA screening and MRI of the prostate. Results showed that men in the MRI-targeted biopsy group had a lower relative risk of detecting clinically insignificant cancer compared to those in the systematic biopsy group. The authors suggest that these findings should prompt updates to guidelines on prostate cancer diagnosis and screening. Further research supports reducing overdiagnosis in men with elevated PSA levels.
Source link
Omitting biopsy with negative MRI reduces detection of clinically insignificant prostate cancer: Study
